Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Free Report) saw a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 176,800 shares, a decrease of 28.7% from the June 30th total of 248,100 shares. Based on an average daily volume of 502,500 shares, the short-interest ratio is currently 0.4 days.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. HC Wainwright reissued a “neutral” rating on shares of Spruce Biosciences in a report on Wednesday, June 5th. Oppenheimer cut their price target on shares of Spruce Biosciences from $4.00 to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, June 13th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Spruce Biosciences has a consensus rating of “Hold” and a consensus target price of $5.00.
Check Out Our Latest Stock Report on SPRB
Institutional Trading of Spruce Biosciences
Spruce Biosciences Stock Performance
Shares of Spruce Biosciences stock remained flat at $0.55 during trading on Friday. 117,589 shares of the stock were exchanged, compared to its average volume of 411,268. The company has a market capitalization of $22.47 million, a price-to-earnings ratio of -0.48 and a beta of 2.41. The stock has a fifty day moving average price of $0.62 and a 200-day moving average price of $1.79. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.67 and a current ratio of 4.67. Spruce Biosciences has a fifty-two week low of $0.50 and a fifty-two week high of $5.95.
Spruce Biosciences (NASDAQ:SPRB – Get Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Spruce Biosciences had a negative net margin of 461.67% and a negative return on equity of 57.53%. The company had revenue of $2.00 million for the quarter, compared to analyst estimates of $1.12 million. On average, analysts predict that Spruce Biosciences will post -1.24 earnings per share for the current fiscal year.
About Spruce Biosciences
Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.
Featured Articles
- Five stocks we like better than Spruce Biosciences
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Is Crypto Cool Again? What Stocks You Should Be Watching
- How to Calculate Options Profits
- Why Call Options Volume for These 2 Stocks Spiked Together
- How to Buy Cheap Stocks Step by Step
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.